Cancer drug developer Oncologie raised $80m from investors including Nan Fung Life Sciences and the Nan Fung-funded Pivotal BioVentures China.

US-based cancer drug developer Oncologie has completed an $80m series B round co-led by Nan Fung Life Sciences, a subsidiary of property developer Nan Fung. Nan Fung co-led the round with Pivotal BioVentures China, a life sciences investment vehicle funded by Nan Fung. It included investment firm Panacea Venture‚Äôs Healthcare fund and private equity firm…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.